miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.
MicroRNAs (miRNAs) are short non-coding RNA molecules, which posttranscriptionally regulate genes expression and play crucial roles in diverse biological processes, such as development, differentiation, apoptosis, and proliferation. Here, we investigated the possible role of miRNAs in the development of multidrug resistance (MDR) in human gastric and lung cancer cell lines. We found that miR-497 was downregulated in both multidrug-resistant human gastric cancer cell line SGC7901/vincristine (VCR) and multidrug-resistant human lung cancer cell line A549/cisplatin (CDDP) and the downregulation of miR-497 was concurrent with the upregulation of BCL2 protein, compared with the parental SGC7901 and A549 cell lines, respectively. In vitro drug sensitivity assay demonstrated that overexpression of miR-497 sensitized SGC7901/VCR and A549/CDDP cells to anticancer drugs, respectively. The luciferase activity of BCL2 3'-untranslated region-based reporter constructed in SGC7901/VCR and A549/CDDP cells suggested that BCL2 was the direct target gene of miR-497. Enforced miR-497 expression reduced BCL2 protein level and sensitized SGC7901/VCR and A549/CDDP cells to VCR-induced and CDDP-induced apoptosis, respectively. Taken together, our findings first suggested that has-miR-497 could play a role in both gastric and lung cancer cell lines at least in part by modulation of apoptosis via targeting BCL2.
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, 210029 Nanjing, People's Republic of China.
Wei
W
Zhu
DanXia
D
Zhu
Shiqiang
S
Lu
Tongshan
T
Wang
Jian
J
Wang
Binghua
B
Jiang
Yongqian
Y
Shu
Ping
P
Liu
D017209:Apoptosis / Q000235:genetics; D015153:Blotting, Western; D045744:Cell Line, Tumor; D018432:Drug Resistance, Multiple / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D019254:Genes, bcl-2; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism; D035683:MicroRNAs / Q000235:genetics*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D013274:Stomach Neoplasms / Q000235:genetics* / Q000378:metabolism
C559640:MIRN497 microRNA, human; D035683:MicroRNAs; D019253:Proto-Oncogene Proteins c-bcl-2
Int J Cancer. 2010 Jan 1;126(1):2-10
19634138
Cell. 2002 Jan 25;108(2):153-64
11832206
Med Oncol. 2010 Jun;27(2):406-15
19412672
Cell. 1993 Dec 3;75(5):843-54
8252621
Pancreas. 2002 Nov;25(4):366-72
12409831
Eur J Cancer. 2010 Jan;46(2):298-311
19948396
Br J Cancer. 2006 Apr 24;94(8):1087-92
16495912
Drug Resist Updat. 2007 Feb-Apr;10(1-2):59-67
17350322
Nat Genet. 2008 Jan;40(1):43-50
18066065
J Biol Chem. 2009 Sep 25;284(39):26533-46
19633292
Br J Cancer. 1992 Nov;66(5):794-9
1419622
Int J Cancer. 2010 Dec 1;127(11):2520-9
20162574
Neurobiol Dis. 2010 Apr;38(1):17-26
20053374
Nat Clin Pract Oncol. 2006 Jul;3(7):388-98
16826219
Nat Rev Drug Discov. 2006 Mar;5(3):219-34
16518375
Cell. 2010 Apr 2;141(1):69-80
20371346
Arzneimittelforschung. 2008;58(6):261-4
18677966
J Mol Biol. 2010 Sep 24;402(3):491-509
20678503
Mod Pathol. 2009 Feb;22(2):197-205
18677302
Cancer Gene Ther. 2010 Aug;17(8):523-31
20467450
Semin Oncol. 2003 Oct;30(5 Suppl 16):133-42
14613034
Brain Res. 2009 Aug 25;1286:13-8
19559015
Drug Resist Updat. 2010 Jun;13(3):57-66
20236855
Methods. 2001 Dec;25(4):402-8
11846609
JAMA. 2007 May 2;297(17):1901-8
17473300
Int J Oncol. 1998 Apr;12(4):871-82
9499449
Int J Cancer. 2008 Jul 15;123(2):372-379
18449891
Cancer Treat Rev. 2007 Feb;33(1):9-23
17084534